MIP Technologies will collaborate with Sanofi-Aventis in the development of molecularly imprinted polymers for the analysis of pharmacologically active peptides from plasma samples.
MIP Technologies will use a number of its molecular imprinting methods in the development of the polymers.
The use of molecularly imprinted polymers for selective recognition of peptides and proteins is a novel area that will open up the technology to numerous applications in the diagnostic, pharmaceutical and biopharmaceutical industries.
Sanofi-Aventis will have exclusive access for use of the polymer in the analysis of proprietary peptide candidates, while MIP Technologies will retain the rights to use the polymers for other applications.
The incorporation of the polymer into the Sanofi-Aventis analytical methods will make use of separation cartridges, which will be provided through MIP Technologies' exclusive partnership in analytical products with Supelco, a division of Sigma Aldrich.
MIP material developed during the collaboration may also be usable for selective peptide purification at preparative or process scale.
Financial terms were not disclosed.
